PODD - Insulet Corp Stock Analysis
Insulet Corp (PODD) is a publicly traded company listed on the Large. It operates in the Medical Devices industry, part of the broader Healthcare sector. The company has a market capitalization of 10.56B, generates annual revenue of 2.90B, and reports net income of 302.80M. As of the latest data, the stock is trading at 152.49 USD.
From a valuation and risk perspective, the stock presents the following profile: The stock is moderately valued and aligns with market expectations for established companies. The PEG ratio is below 1, which may indicate the stock is undervalued relative to its growth potential. The company maintains a healthy balance between debt and equity, which is typical for stable businesses. This stock does not currently pay a dividend. The stock has average market volatility, aligning with general market movement.
Analyst recommendation stands at Buy (4.18), indicating current market sentiment. Institutional ownership is reported at 104.18%, reflecting confidence from large investors. Over the last 12 months, the stock has shown a performance of -53.04%, trading within a 52-week range of 145.59 - 354.88.
PODD - Insulet Corp
152.49
Analyst Consensus
Buy 4.18
PODD – Analyst Rating Summary
- Strong Buy: 12
- Buy: 17
- Hold: 4
- Sell: 1
- Strong Sell: 0
- Total Analysts: 34
| Index: | S&P 500 | P/E: | 35.49 | EPS (ttm): | 4.30 | Insider Own: | 0.41% | Shs Outstand: | 69.26M | Perf Week: | -1.09% |
| Market Cap: | 10.56B | Forward P/E: | 18.75 | EPS next Y: | 8.13 | Insider Trans: | 1.95% | Shs Float: | 68.98M | Perf Month: | -25.15% |
| Income(ttm): | 302.80M | PEG: | 0.69 | EPS next Q: | 1.46 | Inst Own: | 104.18% | Short Float: | 4.30% | Perf Quarter: | -38.10% |
| Revenue(ttm): | 2.90B | P/S: | 3.64 | EPS this Y: | 30.32% | Inst Trans: | -0.94% | Short Ratio: | 2.42 | Perf Half Y: | -54.16% |
| Book/sh: | 18.81 | P/B: | 8.11 | EPS next Y: | 25.56% | ROA: | 9.31% | Short Interest: | 2.97M | Perf Year: | -53.04% |
| Cash/sh: | 6.94 | P/C: | 21.99 | EPS next 5Y: | 27.31% | ROE: | 23.00% | 52W Range: | 145.59 - 354.88 | Perf YTD: | -46.35% |
| Dividend Est.: | - | P/FCF: | 25.41 | EPS past 3/5Y: | 275.33% 102.14% | ROIC: | 13.57% | 52W High: | 354.88 -57.03% | Beta: | 1.17 |
| Dividend TTM: | - | Quick Ratio: | 1.78 | Sales past 3/5Y: | 27.54% 24.53% | Gross Margin: | 71.64% | 52W Low: | 145.59 4.74% | Perf 5Y: | -35.48% |
| Dividend Ex-Date: | - | Current Ratio: | 2.45 | EPS Y/Y TTM: | -24.86% | Oper. Margin: | 17.47% | RSI (14): | 33.55 | Volatility: | 5.23% 5.16% |
| Employees: | 5400 | Debt/Eq: | 0.73 | Sales Y/Y TTM: | 31.93% | Profit Margin: | 10.44% | Recom: | 1.50 | Target Price: | 245.17 |
| Option/Short: | Yes / Yes | LT Debt/Eq: | 0.71 | EPS Q/Q: | 158.51% | Payout: | 0.00% | Rel Volume: | 1.28 | Prev Close: | 147.46 |
| Sales Surprise: | 4.36% | EPS Surprise: | 18.46% | Sales Q/Q: | 33.87% | Earnings: | May 06 BMO | Avg Volume: | 1.22M | Price: | 152.49 |
| SMA20: | -9.26% | SMA50: | -22.30% | SMA200: | -44.50% | Undervalued: 60.78% | Volume: | 1,563,303 | Change: | 3.41% | |
Graham Classic formula value: 243.72
(P/E=8 * 1g) Min value: 136.34
(current P/E * 2g) Max value: 347.93
Average value: 242.66
About Insulet Corp
Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.
Attention! Trading on the stock market involves financial risks and is not suitable for everyone. The www.stocks-expert.com does not provide financial market trading services; it is for informational purposes only and is not responsible for the consequences of your trading decisions or the operation of the software. Before starting to trade in any markets, make sure you understand the risks associated with trading and that you have a sufficient level of training.